在癌症治疗中准dePARylation
Peng Li1, Duo Wu1, Xiaochun Yu1
1Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China; School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China.
多分子ADP-ribosyl化 (PARylation) 是DNA修复的关键. 抑制像PARG这样的dePARylation酶对新型癌症疗法具有前景,与当前的PARP抑制剂不同.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 聚ADP-ribosyl) 化 (PARylation) 是一种关键的翻译后修饰,调节DNA复制和修复.
- 聚 ((ADP-ribose) 聚合酶 (PARPs) 调解PARylation,它们的抑制剂 (PARPi) 对抗BRCA突变癌症有效.
- 通过诸如多ADP-ribose) 糖酶 (PARG) 等酶介导的dePARylation对于DNA损伤反应和基因组稳定性至关重要.
研究的目的:
- 审查dePARylation在维持基因组稳定中的作用.
- 为了探索在癌症治疗中使用多种 (ADP-ribose) 糖酶 (PARG) 抑制剂的治疗潜力.
- 与PARP抑制剂相比,强调PARG抑制剂的独特抗癌机制.
主要方法:
- 关于dePARylation和PARG抑制剂的研究的文献综述.
- 对PARG抑制剂的临床前和临床数据的分析.
- 讨论癌症中PARG抑制的基础分子机制.
主要成果:
- 脱PARylation对于有效的DNA损伤反应和基因组完整性至关重要.
- 新型PARG抑制剂在临床前和临床研究中表现出有前途的抗癌活性.
- 在癌症治疗中,PARG抑制剂提供了一种与PARP抑制剂不同的治疗策略.
结论:
- 通过PARG抑制向dePARylation代表了癌症治疗的一个有希望的途径.
- PARG 抑制剂显示出独特的抗癌潜力,补充了现有的 PARPi 治疗方法.
- 对PARG抑制剂的进一步研究可能会为各种癌症带来新的治疗选择.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Drugs that Destabilize Microtubules
Inhibition of Cdk Activity
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
